Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Dignass

Showing results (91-100 of 177) with videos related to

Pageof 18
Sort By:
Gastroenterology|June 23, 2019
Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel DiseasesParambir S Dulai, Laurent Peyrin-Biroulet, Silvio Danese, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 30, 2021
Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel diseasePaula Sousa, Paula Ministro, Alessandro Armuzzi, et al.
Journal of Crohn'S & Colitis|May 18, 2017
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current ManagementMarcus Harbord, Rami Eliakim, Dominik Bettenworth, et al.
Inflammatory Bowel Diseases|March 4, 2026
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension studyBruce E Sands, David B Clemow, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|February 19, 2014
Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trialAxel Dignass, Simeon Stoynov, Andrey E Dorofeyev, et al.
Journal of Crohn'S & Colitis|November 9, 2025
Establishing a multiple outcome set for Crohn's disease in real-world evidence studies: results from a Delphi e-surveyPaula Leão Moreira, Axel Dignass, Maria Manuela Estevinho, et al.
Journal of Crohn'S & Colitis|November 1, 2017
Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current ManagementMarcus Harbord, Rami Eliakim, Dominik Bettenworth, et al.
Journal of Crohn'S & Colitis|December 3, 2010
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosisGert Van Assche, Axel Dignass, Julian Panes, et al.
Journal of Clinical Medicine|February 11, 2023
iSTART-II: An Update on the i Support Therapy-Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative ColitisFerdinando D'Amico, Fernando Magro, Benedicte Caron, et al.
Transplantation|August 19, 2003
Successful infliximab treatment of steroid and OKT3 refractory acute cellular rejection in two patients after intestinal transplantationAndreas Pascher, Cornelia Radke, Axel Dignass, et al.
Pageof 18

Showing results (91-100 of 177) with videos related to

Sort By:
Pageof 18
Gastroenterology|June 23, 2019
Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel DiseasesParambir S Dulai, Laurent Peyrin-Biroulet, Silvio Danese, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 30, 2021
Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel diseasePaula Sousa, Paula Ministro, Alessandro Armuzzi, et al.
Journal of Crohn'S & Colitis|May 18, 2017
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current ManagementMarcus Harbord, Rami Eliakim, Dominik Bettenworth, et al.
Inflammatory Bowel Diseases|March 4, 2026
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension studyBruce E Sands, David B Clemow, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|February 19, 2014
Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trialAxel Dignass, Simeon Stoynov, Andrey E Dorofeyev, et al.
Journal of Crohn'S & Colitis|November 9, 2025
Establishing a multiple outcome set for Crohn's disease in real-world evidence studies: results from a Delphi e-surveyPaula Leão Moreira, Axel Dignass, Maria Manuela Estevinho, et al.
Journal of Crohn'S & Colitis|November 1, 2017
Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current ManagementMarcus Harbord, Rami Eliakim, Dominik Bettenworth, et al.
Journal of Crohn'S & Colitis|December 3, 2010
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosisGert Van Assche, Axel Dignass, Julian Panes, et al.
Journal of Clinical Medicine|February 11, 2023
iSTART-II: An Update on the i Support Therapy-Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative ColitisFerdinando D'Amico, Fernando Magro, Benedicte Caron, et al.
Transplantation|August 19, 2003
Successful infliximab treatment of steroid and OKT3 refractory acute cellular rejection in two patients after intestinal transplantationAndreas Pascher, Cornelia Radke, Axel Dignass, et al.
Pageof 18